Novavax, a biotech firm based mostly in Maryland, introduced at the moment that its two-dose vaccine was 96% efficient towards the unique Covid-19 vaccine, although it was much less efficient towards variants.
The firm says that the vaccine is 96% efficient at defending towards gentle, average and extreme illness brought on by the unique Covid-19 virus, which makes it barely extra protecting than the Moderna or Pfizer-BioNTech vaccines.
It’s 86% efficient towards the B.1.1.7 virus that was first found within the U.Ok., however solely 55% efficient towards the B1.351 variant first found in South Africa.
Whatever the variant, nobody within the medical trials who obtained the Novavax vaccine was hospitalized with extreme Covid-19 or died from the illness.
The corporate has already inked offers with nations together with Canada, the U.Ok., Australia and India and expects to have the capability to fabricate 2 billion doses by mid-2021.
The Novavax vaccine is completely different from the mRNA vaccines and the single-dose Johnson & Johnson vaccine which have already been licensed within the U.S. This vaccine is made up of nanoparticles that mimic the Covid-19 spike protein. When injected, immune cells within the physique react to the vaccine and create antibodies that can block the SARS-Cov-2 virus if the physique will get contaminated sooner or later. The nanoparticle vaccine can’t make you sick or offer you Covid-19.
What To Watch For
The following step for the corporate might be to use for Emergency Use Authorization from the FDA. In its latest earnings report, Novavax stated that it’s in ongoing conversations with the FDA and will file for an EUA as early as Q2 2021.
95.7 million. That’s what number of doses of Covid-19 vaccines have been administered thus far within the U.S.